The impact of chemotherapy on cognitive function: a multicentre prospective cohort study in testicular cancer

Support Care Cancer. 2020 Jul;28(7):3081-3091. doi: 10.1007/s00520-019-05095-3. Epub 2019 Oct 23.

Abstract

Purpose: The causal link between chemotherapy and cognitive impairment is unclear. We studied testicular cancer patients' objective and subjective cognitive function longitudinally, comparing a surgery group with a surgery + chemotherapy group, addressing prior methodological issues using a computerized test to limit assessment issues, and controlling for confounding variables.

Methods: Prospectively, of 145 patients from 16 centres with sufficient data, n = 61 receiving surgery + chemotherapy (etoposide and cisplatin ± bleomycin, BEP/EP; or single agent carboplatin) were compared to n = 41 receiving surgery alone. CogHealth assessed six objective cognitive tasks. The Cognitive Failures Questionnaire assessed self-perceived cognitive dysfunction. The Functional Assessment of Chronic Illness Therapy-Fatigue and the Hospital Anxiety and Depression Scale assessed psychological influences. Linear mixed models compared changes from baseline (< 6 months post-surgery/pre-chemotherapy) to follow-up (12-18 months post-baseline), controlling covariates.

Results: There were no significant interaction effects for five objective cognitive function tasks suggesting that changes over time were not due to group membership. However, psychomotor function (controlling for age) and physical well-being were significantly worse for the chemotherapy versus the surgery group at baseline, with groups converging by follow-up. Groups showed no differences in subjective cognitive dysfunction. The chemotherapy group showed higher anxiety, poorer functional well-being and worse fatigue compared to the surgery-only group at baseline, but not by follow-up. For both groups, emotional well-being, functional well-being and anxiety significantly improved over time.

Conclusion: No substantive differences in objective or subjective cognitive dysfunction in either group persisted 12-18 months post-baseline. Patients undergoing chemotherapy for testicular cancer differ from findings in breast cancer populations.

Trial registration: ClinicalTrials.gov Identifier: ACTRN12609000545268.

Keywords: Chemotherapy; Cognitive function; Mood; Quality of life; Surgery; Testicular cancer.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bleomycin / administration & dosage
  • Bleomycin / adverse effects
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / psychology
  • Carboplatin / adverse effects*
  • Carboplatin / therapeutic use
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cognition / drug effects*
  • Cognitive Dysfunction / chemically induced*
  • Etoposide / administration & dosage
  • Etoposide / adverse effects
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prospective Studies
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / psychology*
  • Testicular Neoplasms / surgery

Substances

  • Bleomycin
  • Etoposide
  • Carboplatin
  • Cisplatin